Compare · PYPD vs WST
PYPD vs WST
Side-by-side comparison of PolyPid Ltd. (PYPD) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PYPD and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $28.74B, about 224.2x PYPD ($128.2M).
- Over the past year, PYPD is up 74.6% and WST is up 49.0% - PYPD leads by 25.6 points.
- WST has been more active in the news (7 items in the past 4 weeks vs 6 for PYPD).
- WST has more recent analyst coverage (20 ratings vs 7 for PYPD).
- Company
- PolyPid Ltd.
- West Pharmaceutical Services Inc.
- Price
- -
- -
- Market cap
- $128.2M
- $28.74B
- 1M return
- +33.30%
- +11.17%
- 1Y return
- +74.60%
- +49.00%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 6
- 7
- Recent ratings
- 7
- 20
PolyPid Ltd.
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest PYPD
- PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results
- PolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11, 2026
- SEC Form 6-K filed by PolyPid Ltd.
- PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections
- Oppenheimer initiated coverage on PolyPid Ltd. with a new price target
- PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026
- PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026
- SEC Form 6-K filed by PolyPid Ltd.
- European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀
- SEC Form 6-K filed by PolyPid Ltd.
Latest WST
- Amendment: SEC Form SCHEDULE 13G/A filed by West Pharmaceutical Services Inc.
- West to Participate in Upcoming Investor Conference
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- SEC Form 8-K filed by West Pharmaceutical Services Inc.
- West Reports Third-Quarter 2026 Results
- SEC Form 8-K filed by West Pharmaceutical Services Inc.
- West Declares Quarterly Dividend
- West to Host Third-Quarter 2026 Conference Call
- West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide
- SEC Form 4 filed by Director Haugen Janet Brutschea